MAPS Europe B.V.

MAPS Europe B.V. is an Amsterdam-based Dutch subsidiary of the Multidisciplinary Association for Psychedelic Studies that operates as a clinical trial sponsor for MDMA-assisted psychotherapy research in Europe. Its public-facing work centers on advancing prescription pathways for MDMA in the treatment of post-traumatic stress disorder and coordinating regulated clinical research across multiple European sites.

Its role in the field is primarily research and access-oriented rather than broad drug policy advocacy. Public protocol materials describe a multicenter European open-label Phase 2 study for PTSD, with therapy-team training and a planned Phase 3 lead-in, suggesting a focus on clinical evidence generation, therapist preparation, and regulatory submission support. For researchers, clinicians, funders, and policy groups, the most relevant collaboration opportunities appear to be trial participation, clinical training, implementation planning, and evidence-to-regulation work for MDMA-assisted psychotherapy.